Company news
Therma Bright Inc. (TSXV:THRM) news
Therma Bright Inc. news releases on 6ix. Latest, Feb 6, 2024: Therma Bright's Venowave Accepted for Review By Center for Medicare & Medicaid Services…
Press releases — page 2
Therma Bright's Venowave Accepted for Review By Center for Medicare & Medicaid Services for Permanent CPT and HCPCS codes
February 6, 2024
Therma Bright Provides Update on Cease Trade Order
December 5, 2023
Canadian Investment Regulatory Organization Trading Halt - THRM
December 5, 2023
Therma Bright Prepares FDA 513(g) Review Document for its AI-Driven Digital Cough Analyzer (DCA)
November 29, 2023
Therma Bright Announces Venowave Pilot Tests with Existing and New Distribution Partners in the United States
November 2, 2023
TSX Venture Exchange Stock Maintenance Bulletins
October 24, 2023
Therma Bright Announces New CFO
September 29, 2023
Therma Bright Announces Change of Auditor
September 29, 2023
Therma Bright Announces Amendments to InStatin & InVixa Acquisitions
September 27, 2023
Therma Bright Adds Hero LifeCare as Northeast Venowave Distribution Partner
September 13, 2023
Therma Bright Submits Updated FDA 510K Application Requesting Correction of Venowave Device's Intended Use, Labeling, and Description
September 7, 2023
Therma Bright Provides Update on Venowave's Permanent CPT/HCPCS Code Application Process
August 22, 2023
Therma Bright CEO says permanent insurance codes for Venowave could be a game changer
August 7, 2023
Therma Bright Provides Update on Venowave's Permanent CPT/HCPCS Codes and United States Distribution Partners
August 4, 2023
Therma Bright Provides Update on Venowave for the United States and Texas Region
June 30, 2023
Therma Bright Investigates Remote Therapeutic Monitoring (RTM) Reimbursement for its AI-Driven Digital Cough Technology
June 22, 2023
Therma Bright's Investment Partner Inretio Announces Successful Completion of GLP Study for PREVA(TM) Thrombectomy Device
June 7, 2023
Therma Bright Expands U.S. Distribution of Venowave Device to Increase Sales Under Temporary CPT(R) & HCPCS Codes
May 25, 2023
Therma Bright Initiates Data Collection with AI Digital Cough Technology App at TB Clinics
May 10, 2023
Therma Bright Milestone Payments Bring Ownership in Inretio to 7.5%
April 21, 2023
Therma Bright Secures Medicare and Medicaid Reimbursement for Venowave Device
April 14, 2023
Therma Bright Prepares Launch of Digital Cough Screening and Data Collection Smartphone Application
March 23, 2023
Therma Bright's Investment Partner Inretio Moves to New Manufacturing Facility
March 8, 2023
Therma Bright, Announces Appointment of Dr. John Patton as Chairman to Investee Company InStatin Inc.
March 1, 2023
Therma Bright Reports on Progress of Inretio's Novel Clot Removal Device for Stroke Treatment
February 23, 2023
Therma Bright Secures Exclusive License Agreement for AI4LYF's Patent-Pending Digital Cough Technology (DCT) to Detect Respiratory Diseases
February 16, 2023
Therma Bright Inc. Invests in Ischemic Stroke Blood Clot Retriever Technology Company Inretio Inc. based in Israel
January 19, 2023
Therma Bright Provides 2022 Year End Update
December 21, 2022
Therma Bright Invests in the Development of Novel Treatments for COVID-19, Asthma, and Chronic Obstructive Pulmonary Disease (COPD)
December 1, 2022
Therma Bright Inc. to Acquire an Exclusive License for a Patented Digital Cough Based Technology to Detect Respiratory Diseases
November 17, 2022
Therma Bright Receives New Billing Codes for Venowave Allowing for Reimbursement from Medicare, Medicaid, and Private Insurers
October 27, 2022
Therma Bright Receives Payment for Initial Venowave Sales
September 20, 2022
Therma Bright Provides Update on FDA EUA Review Process
September 12, 2022
Therma Bright Provides Progress Update on FDA EUA & Health Canada Interim Order Applications for Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
August 4, 2022
Therma Bright Submits Health Canada Application for Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test for Point-of-Care (POC)
June 23, 2022
Therma Bright Grants Stock Options
June 10, 2022
Therma Bright Provides Update on FDA EUA Application Process For AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
June 2, 2022
Therma Bright to Submit Application to Health Canada for Approval of its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
May 10, 2022
Therma Bright Ships Initial Venowave Order to US Distributor
April 28, 2022
Therma Bright Submits AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Application for U.S. Food & Drug Administration's Emergency Use Authorization (EUA)
March 29, 2022
Therma Bright Recognized In 2022 TSX Venture 50 Top Performing Stocks
February 24, 2022
Therma Bright Receives Patent for a Device for Applying a Topical Treatment from U.S. Patent & Trademark Office (USPTO)
February 23, 2022
Therma Bright Announces Closing of CAD$6 Million Private Placement with Institutional Investors
February 18, 2022
Therma Bright Announces CAD$6 Million Private Placement with Institutional Investors
February 16, 2022
Therma Bright's AcuVid(TM) U.S. Clinical Performance Study Successfully Exceeds U.S. Food & Drug Administration's Emergency Use Authorization Requirements
February 15, 2022
Therma Bright Completes U.S. Clinical Performance Study Subject Recruitment
January 31, 2022
Therma Bright Provides Update on U.S. Clinical Performance Study
January 20, 2022
Therma Bright AcuVid(TM) COVID-19 Rapid Antigen Saliva Test's Antibodies Successfully Detect the COVID-19 Omicron B.1.1.529 Variant
December 16, 2021
Therma Bright Expands Manufacturing Capabilities To Meet New FDA EUA Guidance For AcuVid(TM)
December 1, 2021
Therma Bright Launches Benepod.com eCommerce Website
November 24, 2021